STOCK TITAN

HeartSciences Warrant (HSCSW) 424B Filings

HSCSW NASDAQ

Here are the 424B prospectus supplements from HeartSciences Inc. Warrant (HSCSW) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 424B covers the supplement that carries the terms of a priced offering, so if you follow HSCSW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HSCSW filings page.

Rhea-AI Summary

HeartSciences Inc. (HSCS) may offer common stock with an offering price of up to $3,077,649 through Maxim Group LLC under an at-the-market offering, subject to Form S-3's I.B.6 limit. Sales may occur from time to time at market prices; Maxim is not required to sell a set amount. The commission is 2.5% of gross sales while the limit applies and 2.0% thereafter. HeartSciences says it cannot assure it will receive proceeds.

The proposed merger with Fortitude is expected to close in the fourth quarter of 2026, subject to customary conditions including shareholder approval. Nasdaq accepted the company's compliance plan and set February 1, 2027 as the deadline to evidence compliance with its $2.5 million stockholders' equity minimum; HeartSciences reported $226,060 in stockholders' equity in its 2026 annual report. FDA clearance covers the MyoVista wavECG as a 12-lead resting ECG, not an AI algorithm; HeartSciences says it does not currently intend significant additional commercialization resources for that device. The company also disclosed substantial doubt about its ability to continue as a going concern and Fiscal 2026 material weaknesses in financial controls.

Rhea-AI Summary

HeartSciences Inc. (HSCS) is registering common stock for an at-the-market offering with an aggregate offering price of up to $4,161,139 under its Equity Distribution Agreement with Maxim Group LLC. HeartSciences may sell shares from time to time; Maxim is not required to sell a specific amount and will use commercially reasonable efforts. While the aggregate market value of shares held by non-affiliates is below $75 million, sales are subject to Form S-3’s limit of one-third of that value in any 12-month period. HeartSciences reported that market value as $23,159,765 as of October 6, 2026.

As of October 6, 2026, HeartSciences had sold 1,529,287 shares for an aggregate offering price of approximately $14.1 million under the agreement. It also reported approximately $3.6 million in securities sales under the Form S-3 limit during the preceding 12 calendar months. Separately, its proposed transaction under a merger agreement with Fortitude Mining Holdings, Inc., Fortitude Mining HoldCo, LLC, and its subsidiary Cordis Acquisition, LLC is expected to close in the fourth quarter of 2026, subject to customary closing conditions, including HeartSciences shareholder approval.

Rhea-AI Summary

HeartSciences Inc. (Nasdaq: HSCS) filed Prospectus Supplement No. 3 to update its at-the-market (ATM) program with Maxim Group. The Third Amendment to the September 2023 Equity Distribution Agreement lifts the program’s ceiling to $25 million; however, because the company’s non-affiliate public float is only $13.0 million, General Instruction I.B.6 of Form S-3 caps the immediate raise at $14,737,609. To date, 530,057 shares have been sold for ≈$10.4 million.

Maxim will earn a 4.0 % commission on gross proceeds up to $11.0 million and 3.0 % thereafter. The ATM will terminate upon sale of all registered shares, or may be ended at any time by either party. Shares will be offered “at-the-market” on Nasdaq; the last reported price on 31-Jul-2025 was $3.12 per share, while IPO warrants (HSCSW) traded at $0.1184.

The filing notes that no securities have been sold under I.B.6 limitations in the preceding 12 months. If HeartSciences’ public float exceeds $75 million, Form S-3 restrictions will fall away, enabling larger primary offerings. Investors are reminded to review the company’s risk factors incorporated by reference from its latest 10-K and 10-Q.